Eupraxia Pharmaceuticals Inc(EPRX-T)
TSX

Today's Change
Real-Time Last Update
Day Low9.40
Day High9.66
Open:9.43
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
GlobeNewswire
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
GlobeNewswire
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
GlobeNewswire
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
GlobeNewswire
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
GlobeNewswire
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
GlobeNewswire
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis 
Newsfile
Upcoming Meeting Dates - April 20, 2026
GlobeNewswire
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
GlobeNewswire
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
GlobeNewswire
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
GlobeNewswire
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
GlobeNewswire
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
GlobeNewswire
Eupraxia Pharmaceuticals Announces Proposed Public Offering

Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.